Aciex Therapeutics, Inc.

Quick facts

Phase 3 pipeline

• AC-170 0% · Diabetes
  AC-170 is a small molecule that targets the SGLT2 receptor.
• AC-170 0.24% · Ophthalmology
  AC-170 is a topical ophthalmic agent that reduces intraocular pressure, likely through enhanced aqueous humor outflow or reduced production.
• Drug: AC-170 0.24% · Ophthalmology
  AC-170 is a topical ophthalmic agent that reduces intraocular pressure, likely through enhanced aqueous humor outflow or reduced production.

Phase 2 pipeline

• AC-150 Combo
• AC-150A 0.1% · Dermatology
  AC-150A 0.1% is a topical corticosteroid used to reduce inflammation and itching in various skin conditions.
• AC-150B 0.005% · Dermatology
  AC-150B 0.005% is a topical corticosteroid used to reduce inflammation and itching.
• AC-170 0.05% · Diabetes
  AC-170 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
• AC-170 0.1% · Diabetes
  AC-170 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2).

Phase 1 pipeline

• AC-170 0.17%

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Aciex Therapeutics, Inc. portfolio CI brief
• Aciex Therapeutics, Inc. pipeline updates RSS